IDH2 and astrocytoma (excluding glioblastoma): Here we compare a large cohort of long-term survivors with an OS of 15 years or longer after diagnosis of an IDH-mutant oligodendroglioma or astrocytoma with a reference group of patients with less favourable outcome to determine prognostic factors for long-term survival.